


## REMARKS/ARGUMENTS

Claims 1-29 are pending in this application. An election under 35 U.S.C. § 121 has been required to the subject matter of:

1. A disclosed species of sympathomimetic drug (i.e. Claim 2).
2. A disclosed species of piperidinoalkanol compound (i.e. Claim 4) wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $Z$ ,  $m$  and  $n$  are specifically defined.
3. Identify a definition for  $X$  in formulas IIIa and IIIb in Claims 6 and 7.

Applicants elect the following species without traverse. All of the pending claims read on the following species.

1. Species of sympathomimetic drug: pseudoephedrine
2. Species of piperidinoalkanol compound: fexofenadine and salts thereof having the following structure



3. Definition of  $X$  in formulas IIa and IIIb in Claims 6 and 7: 0 or 1

Applicants expressly reserve the right to file divisional applications directed to the non-elected subject matter. The Examiner is invited to contact the undersigned by telephone if there are any questions concerning this response.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(609) 627-8508

Date: 8/15/07

Joseph T. Majka  
Attorney for Applicants  
Reg. No. 30,570